Drug discovery startup Predix Pharmaceuticals didn’t have to look far to raise additional money to support its goal of moving its first compound into clinical trials by the end of the year. The company shared a key investor with Physiome Sciences, which had been rethinking its business model since the departure of CEO Jeremy Levin in April.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.